[1] |
LI Xingren, SHEN Aizong, SU Dan.
Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
|
[2] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[3] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[4] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[5] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[6] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[7] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|
[8] |
YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang.
Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
|
[9] |
ZHENG Jinfeng, WANG Jinghong.
Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
|
[10] |
SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying.
Pharmaceutical care of a patient with indapamide-induced agranulocytosis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
|
[11] |
WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui.
Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
|
[12] |
WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui.
Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.
|
[13] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[14] |
SUN Xuelin, ZHANG Pan, HU Xin.
Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.
|
[15] |
TANG Jingya.
Pharmaceutical care by a clinical pharmacists in the treatment of parenteral nutrition related hepatic damage: a case report
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 786-788.
|